WHO technical Series 1010 Annex 10 - Stability study requirements for Finished product Pharmaceuticals

WHO stability guideline Annex 10 is a document that provides the core stability data package required for registration of APIs and finished pharmaceutical products (FPPs). It covers the general principles of stability testing, the types of studies, the storage conditions, the specifications, the testing frequency, the stability commitment, the evaluation, the statements and the labelling. It also includes some annexes on photostability testing, bracketing and matrixing, and statistical analysis.

The article discusses the requirements of FP pharmaceuticals only.

Guidance expects the design of the stability study for the Finished Product to be based on Knowledge of the behavior and properties of the API, information from the stability study of the API and experience gained from the pre-formulation studies, similar formulations and investigational FPPs.

Investigational drug products are the pharmaceutical drugs that are being studies in clinical trials to study their safety and efficacy for the specific medical conditions. These are not Approved by the Regulatory agencies for marketing and use for general population.

Investigational drugs go through a series of clinical trials, which are carefully designed and controlled studies involving human participants. These trials have different phases, including Phase I, Phase II, and Phase III, each with specific objectives related to safety, efficacy, and dosage.

Stress Testing – Stress testing to be performed on at least one primary batch of FPP depending on the formulation type, studies like cyclic studies for semi-solid products or freeze–thaw studies for liquid products.

Cyclic studies involve subjecting the products to a series of temperature and humidity variations to simulate real-world conditions and evaluate their stability to determine how a semi-solid product's quality changes over time, especially when exposed to environmental factors such as temperature and humidity fluctuations. The duration may depend upon the shelf life of the product ranging from few weeks to months.

Freeze-thaw studies are a type of stability testing conducted on pharmaceuticals, biological products, and other substances to assess their stability when subjected to cycles of freezing and thawing. During freeze-thaw studies, samples of the product are exposed to controlled freezing and thawing conditions. These conditions involve subjecting the product to extremely low temperatures (typically below freezing) for a specified duration, followed by thawing at a controlled rate.

Thawing is the process of allowing a frozen or extremely cold item to return to a higher temperature, typically closer to its natural or intended state, which is usually at or near room temperature or above freezing. It's the opposite of freezing, where a liquid or solid is cooled below its freezing point to become solid ice.

  • Selection of batches – 3 PPQ batches of each proposed strength and yearly one commercial batch manufactured by the same manufacturing process packed in same container closure system as proposed for marketing. Wherever possible, batches should be manufactured using different batches of the API to have a better picture of the reproducibility.

  • Container Closure System – Stability testing should be conducted on the dosage form packaged in the primary container-closure systems proposed for marketing.

  • Conditions of exposure and testing: 

  1. Long term – 25 ± 2ºC / 65% ± 5% RH* - every three (3) months over the 1st year, every 6th month over the 2nd ear and annually thereafter till the shelf life 
  2. Intermediate condition - 30 ± 2ºC / 65% ± 5% RH – a minimum of 4 time points i.e. initial, 6 months, 9 months and 12 months
  3. Accelerated condition - 40 ± 2ºC / 75% ± 5% RH – a minimum of 3 time points including initial testing i.e. 0, 3 months and 6 months.
  4.         * Conditions may vary based on the regional requirements

  • Studies like orientation of the products i.e. upright, on the side or the inverted to be considered based on the expected contact of the product with the closure system e.g. in case of liquid s and semisolids.

  • Storage conditions should be monitored. Any excursions due to the equipment failures must be assessed that could affect the stability results. Excursions more than 24 hours must be addressed in stability report and their effects must be assessed.

  • Specification: Relevant Physical, chemical, microbiological and biological parameters with the acceptance criteria using a validated and stability indicating method.

A stability indicating method is the method that is capable to detect and quantify any degradation products, impurities or changes in the active ingredients during manufacturing, storage, transportation or use.

  • Products with preservative contents should be tested for antimicrobial preservative on at least one primary FP batch for the effectiveness of antimicrobial preservative (in addition to preservation content).Micro biological testing – Long term – 25 ± 2ºC / 65% ± 5% RH* - Initial, yearly till the end of the shelf lifeIntermediate condition - 30 ± 2ºC / 65% ± 5% RH – Initial and 12 M if significant change observed at Accelerated condition.Accelerated condition - 40 ± 2ºC / 75% ± 5% RH - Initial, 3rd and 6th month

  • At least one batch annually in every strength packed with each primary packing material to be included in stability program.

  • Additional stability may be required if the significant change or significant deviation during the process or the container closure system.

  • Change requiring supporting data includes:

           -          Changes to AP storage condition or API retest period

           -          Changes in FP formulation, manufacturing process, container closure system, shelf life,                           in-use period storage condition

           -          Other changes such as certain changes to the API certificate of suitability, certificate of                             Pre-qualification, manufacturing site or the manufacturing process or certain changes to                           FPP manufacturing site, batch size or container closure system requirement a                                           commitment of stability study to support the variation

  • Any reworking, reprocessing or recovery operation to be considered for the conclusion in stability study.

Data submission:

For any failures i.e. significant change observed during long term storage condition (25 °C ± 2 °C/60% RH ± 5% RH), Intermediate study to be initiated and submission data should include the intermediate stability data up to 6 months of 12 months data.


  • In-Use and Hold time stability for the multidose products after opening, dilution or reconstitution: 30 days in-use period normally considered acceptable without further supporting data.To be performed on minimum two primary batches, at least pilot scale batch. At least one of these batches should be chosen at the end of shelf life.

Comments